Improving the ex vivo expansion of human tumor-reactive CD8 + T cells by targeting toll-like receptors.
Qiu C, Wang J, Zhu L, Cheng X, Xia B, Jin Y, Qin R, Zhang L, Hu H, Yan J, Zhao C, Zhang X, Xu J.
Qiu C, et al. Among authors: xia b.
Front Bioeng Biotechnol. 2022 Oct 31;10:1027619. doi: 10.3389/fbioe.2022.1027619. eCollection 2022.
Front Bioeng Biotechnol. 2022.
PMID: 36394017
Free PMC article.